 9. Concurrent or prior within 14 days of study day 1 use of strong CYP3A4 inhibitors including, but not limited to, ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole. 